Wockhardt has been manufacturing vaccines for over two decades and the company has a state-of-the-art vaccine manufacturing facility in the United Kingdom (UK) that has been a key contributor to the global fight against COVID-19. The facility was one of the first in the world to start manufacturing the COVID-19 vaccine developed by AstraZeneca and Oxford University.

The facility is located in Wrexham, North Wales, and is capable of producing millions of doses of vaccines each week. The Wrexham facility was established in 1997 and was acquired by Wockhardt in 2003. The company’s COVID-19 vaccine, which was developed in partnership with the UK government and Oxford University, is also manufactured at this facility.

The facility is equipped with advanced technologies and has a team of experienced scientists and researchers who are dedicated to manufacturing high-quality vaccines. The facility has several manufacturing lines, which allows it to produce multiple vaccines simultaneously.

Wockhardt UK has entered into a partnership with the Serum Institute of India to manufacture vaccines in the United Kingdom. Wockhardt and Serum to build new state-of-the-art vaccine manufacturing facility in Wrexham, UK to manufacture the COVID-19 vaccine developed by Serum Institute of India.

Wockhardt also has a state-of-the-art vaccine manufacturing facility located in Shendra, India, where the company has the capabilities to manufacture vaccine products. The facility is equipped with advanced technologies and has a team of experienced scientists and researchers who are dedicated to manufacturing high-quality vaccines.

During the COVID-19 pandemic, Bulk vaccine manufacturing facility at Waluj, Aurangabad and drug product facility at Shendra, Aurangabad were inspected and approved by the State FDA and CDSCO, India, as part of the approval process for Sputnik vaccines. The facilities were approved to export 1 billion vaccine doses.

In conclusion, Wockhardt’s vaccine business has been a key growth driver for the company in recent years. The company’s focus on research and development, state-of-the-art manufacturing facilities, and global presence has enabled it to become a leading player in the vaccine market. With the increasing demand for vaccines, Wockhardt is well-positioned to continue its growth trajectory in the coming years.